» Articles » PMID: 29740676

Adverse Reactions Associated with First-line Regimens in Patient Initiating Antiretroviral Therapy

Overview
Specialty Pharmacology
Date 2018 May 10
PMID 29740676
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the prevalence of adverse drug reactions (ADR) and associated factors during the use of Highly Active Antiretroviral Therapy (HAART) in patients initiating treatment.

Methods: This is a cross-sectional analysis of a prospective study conducted in three public referral services specialized in HIV/AIDS care in Belo Horizonte, Brazil. Self-reported ADR and explanatory variables were obtained from face-to-face interview and from Information Systems. Associated factors with ADR were evaluated by logistic regression in SPSS software v.22.

Results: We included 399 patients, of which 85.5% reported at least one and 72.7% up to 5 ADRs after HAART initiation. Neurological reactions were the most frequent, with self-reported ADRs being distinct according to HAART regimen used. The global model showed higher chance of ADRs among females (OR = 3.52) and illicit drug users (OR = 2.28). Lower chance of ADRs was found for patients aged > 33 years (OR = 0.37), DTG/TDF/3TC users (OR = 0.41), and higher physical domain of quality of life (OR = 0.78). The model restricted to patients using the single-tablet regimen EFV/TDF/3TC showed lower ADRs among patients with CD4+ T lymphocyte count > 200 cells/mm (OR = 0.23) and higher independence domain of quality of life (OR = 0.74). The model restricted to DTG/TDF/3TC and to other regimens showed lower ADRs with higher physical domain of quality of life (OR = 0.74 and OR = 0.55, respectively).

Conclusions: The prevalence of self-reported ADRs to first-line antiretroviral regimens was high and patients using DTG/TDF/3TC had a smaller number of ADRs. In addition to HAART regimen, sociodemographic, clinical, and quality of life characteristics were associated with ADRs.

Citing Articles

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens.

Silva G, Mendicino C, Menezes de Padua C, Tupinambas U Einstein (Sao Paulo). 2023; 21:eAO0156.

PMID: 37255057 PMC: 10219625. DOI: 10.31744/einstein_journal/2023AO0156.


Reporting and recording of adverse drug reactions of highly active antiretroviral therapy by HIV infected patients and healthcare professionals respectively in the Ethekwini Metropolitan of Kwa-Zulu Natal, South Africa: a cross-sectional and....

Zondi S, Naidoo P Pan Afr Med J. 2023; 42:218.

PMID: 36845236 PMC: 9949296. DOI: 10.11604/pamj.2022.42.218.32239.


HIV and Substance Use in Latin America: A Scoping Review.

Huff H, Carcamo P, Diaz M, Conklin J, Salvatierra J, Aponte R Int J Environ Res Public Health. 2022; 19(12).

PMID: 35742448 PMC: 9222977. DOI: 10.3390/ijerph19127198.


Health-Related Quality of Life and Coping Strategies in a Cohort Study of Highly Active Antiretroviral Therapy Naïve Patients Adherence.

de Oliveira Franca P, Ayres L, Pimassoni L, Cerutti Junior C Int J Clin Pract. 2022; 2022:8341638.

PMID: 35685558 PMC: 9159168. DOI: 10.1155/2022/8341638.


Quality of life in individuals initiating antiretroviral therapy: a cohort study.

Pimentel G, Ceccato M, Costa J, Mendes J, Bonolo P, Silveira M Rev Saude Publica. 2020; 54:146.

PMID: 33331489 PMC: 7726918. DOI: 10.11606/s1518-8787.2020054001920.


References
1.
Santos W, Secoli S, de Mello Padoin S . Potential drug interactions in patients given antiretroviral therapy. Rev Lat Am Enfermagem. 2016; 24:e2832. PMC: 5173305. DOI: 10.1590/1518-8345.1193.2832. View

2.
OConnell K, Skevington S, Saxena S . Preliminary development of the World Health Organsiation's Quality of Life HIV instrument (WHOQOL-HIV): analysis of the pilot version. Soc Sci Med. 2003; 57(7):1259-75. DOI: 10.1016/s0277-9536(02)00506-3. View

3.
Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi E, Antinori A, Gatti F . Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. HIV Med. 2009; 11(2):104-13. DOI: 10.1111/j.1468-1293.2009.00750.x. View

4.
Namme Luma H, Doualla M, Choukem S, Temfack E, Ashuntantang G, Joko H . Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study. Pan Afr Med J. 2012; 12:87. PMC: 3473973. View

5.
Despiegel N, Anger D, Martin M, Monga N, Cui Q, Rocchi A . Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada. Infect Dis Ther. 2015; 4(3):337-53. PMC: 4575289. DOI: 10.1007/s40121-015-0071-0. View